Which emerging biomarkers have the most potential to affect personalized care of our patients with NSCLC? Read my thoughts on testing for and targeting RET, MET exon 14, and more.
As targeted therapy prolongs survival in our patients with oncogene-driven NSCLC, CNS metastases and leptomeningeal carcinomatosis are more likely to develop as part of the disease course. Read my thoughts on what factors I consider when treating these challenging disease manifestations.
Vamsidhar Velcheti, MD, provides his thoughts on the clinical implications of the recent approval of selpercatinib for RET fusion–positive NSCLC in this commentary.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.